ReviewOncoimmunology2026
Transglutaminase 2 regulates innate immunity: mechanisms and therapeutic implications.
Review in Oncoimmunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- IRES Mutation Confers a Replicative Advantage to SVA by Enhancing Translation Efficiency.Transboundary and emerging diseases · 2026Article
- Elucidating molecular mechanisms of allergic sensitization to olive pollen through transcriptomics.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Innate immunity constitutes the primary barrier against invading pathogens and plays a crucial role in coordinating the initiation and modulation of adaptive immune responses. Transglutaminase 2 (TG2), a ubiquitously expressed multifunctional enzyme, has recently been identified as a key regulator of innate immune signaling. Mounting evidence highlights TG2's involvement in modulating type I interferons and pro-inflammatory cytokines in response to microbial infections and cellular stress, serving as an critical element in diverse signaling pathways. TG2 engages in various immune-related processes, such as inflammation, phagocytosis, and host defense, by integrating into essential intracellular signaling cascades. In this review, we synthesize the current knowledge of TG2's roles in the innate immune system, emphasizing its interactions with TBK1 (TANK-binding kinase 1)-a central node in type I interferon signaling-and other innate immune mediators. We also examine the implications of TG2 dysregulation in immune-mediated diseases and evaluate its promise as a therapeutic target. Collectively, this review integrates recent progress and encourages further exploration of TG2's multifaceted contributions to innate immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.